COGNITION THERAPEUTICS INCCGTXEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for neurodegenerative and neuropsychiatric disorders including Alzheimer’s disease and dementia. Its core pipeline targets underlying disease mechanisms, with U.S. operations and partnerships to advance treatments for global patient populations.
CGTX Q1 FY2024 Key Financial Metrics
Revenue
$-10.0K
Gross Profit
N/A
Operating Profit
$-14.1M
Net Profit
$-9.2M
Gross Margin
N/A
Operating Margin
141020.0%
Net Margin
91510.0%
YoY Growth
0.0%
EPS
$-0.27
COGNITION THERAPEUTICS INC Q1 FY2024 Financial Summary
COGNITION THERAPEUTICS INC reported revenue of $-10.0K (up 0.0% YoY) for Q1 FY2024, with a net profit of $-9.2M (down 48.3% YoY) (91510.0% margin).
Key Financial Metrics
| Total Revenue | $-10.0K |
|---|---|
| Net Profit | $-9.2M |
| Gross Margin | N/A |
| Operating Margin | 141020.0% |
| Report Period | Q1 FY2024 |
Income Statement
| Q1 2024 | |
|---|---|
| Revenue | $-10000 |
| YoY Growth | 0.0% |
Balance Sheet
| Q1 2024 | |
|---|---|
| Assets | $38.9M |
| Liabilities | $10.0M |
| Equity | $28.9M |
Cash Flow
| Q1 2024 | |
|---|---|
| Operating CF | $-7.2M |